• CalciMedica amended its Avenue Venture Opportunities Fund II loan, creating an unregistered conversion feature for up to $3 million of principal.
• Conversion can be into common stock at $1 per share or into pre-funded warrants priced at $0.9999 per underlying share.
• The lender also received an unregistered warrant to buy 1,000,000 shares at $1, exercisable until June 23, 2031.
• Terms extend interest-only payments to Sept. 30, 2027, push maturity to Sept. 1, 2029, raise the final payment fee by $200,000.
• Conversions or exercises are capped by a beneficial ownership limit of up to 19.99%, with pre-funded warrants used to stay within limits.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-280223), on June 24, 2026, and is solely responsible for the information contained therein.